Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.48 |
| ▸ | EPAS1 | Q99814 | 7/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL670927 | 0.98 | RAPGEF4 (0.47) | RAPGEF4EPAS1GRM4IDO1MAOB | |
| SCHEMBL486657 | 0.82 | IDO1 (0.50) | RAPGEF4IDO1ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL2075947 | 0.82 | CA12 (0.45) | RAPGEF4EPAS1IDO1ALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL379523 | 0.79 | IDO1 (0.48) | RAPGEF4IDO1ALDH1A1CYP1A2CYP2C9 | |
| Water SCHEMBL29052961 | 0.79 | IDO1 (0.48) | RAPGEF4IDO1ALDH1A1CYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL718965 | 0.79 | CA12 (0.43) | RAPGEF4IDO1MAOBALDH1A1CYP1A2 | |
| SCHEMBL4185946 | 0.78 | RAPGEF4 (0.50) | RAPGEF4EPAS1GRM4MAOBMEN1 | |
| SCHEMBL1638576 | 0.76 | RAPGEF4 (0.53) | RAPGEF4EPAS1GRM4MAOBMEN1 | |
| SCHEMBL9632275 | 0.74 | MEN1 (0.50) | GRM4IDO1MAOBALDH1A1MEN1 | |
| SCHEMBL1360451 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593453-B1 | AZAINDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-17 | — | — | EP | disclosed |
| US-8673922-B2 | Azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130184254-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2013-07-18 | — | — | US | disclosed |
| CN-103201262-A | Autotaxin inhibitors and uses thereof | AMIRA PHARMACEUTICALS INC | 2013-07-10 | — | — | CN | disclosed |
| WO-2013096744-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| CN-103140490-A | Azaindazole compounds | BRISTOL MYERS SQUIBB CO | 2013-06-05 | — | — | CN | disclosed |
| EP-2593453-A1 | AZAINDAZOLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012009510-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184254-A1 | AZAINDAZOLE COMPOUNDS | CYP3A4, CYP4B1, CYP3A43 | RAPGEF4 1687/4885EPAS1 4164/4885GRM4 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.